Aaron Goodman: Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared an article on X:
“Oncologists should we do this? Or just delay BTKi until relapse.
Seems to me giving upfront BTKi just delays giving it later?
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma | Journal of Clinical Oncology.”
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Authors: Michael Wang, David Salek, David Belada, Yuqin Song, Wojciech Jurczak, Brad S. Kahl, Jonas Paludo, Michael P. Chu, Iryna Kryachok, Laura Fogliatto, Chan Y. Cheah, Marta Morawska, Juan-Manuel Sancho, Yufu Li, Caterina Patti, Cecily Forsyth, Jingyang Zhang, Robin Lesley, Safaa Ramadan, Simon Rule, Martin Dreyling.
You can read the Full Article on Journal of Clinical Oncology.
More posts featuring Aaron Goodman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023